Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

FDA Approves First Targeted Therapy for Dermatomyositis

Summary by mykxlg.com
Approval of LISRAYA™ (brepocitinib) marks a significant scientific and clinical milestone for people living with this

4 Articles

mykxlg.commykxlg.com
Reposted by
Muscular Dystrophy AssociationMuscular Dystrophy Association
Center

FDA Approves First Targeted Therapy for Dermatomyositis

Approval of LISRAYA™ (brepocitinib) marks a significant scientific and clinical milestone for people living with this

Read Full Article
Enid News & EagleEnid News & Eagle
Reposted by
pmg-ky3.compmg-ky3.com
Lean Left

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Thursday, August 27, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Pharma icon

Pharma

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal